Last reviewed · How we verify
IMG-007
At a glance
| Generic name | IMG-007 |
|---|---|
| Sponsor | Inmagene LLC |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis (PHASE2)
- A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of IMG-007 in Adult Alopecia Areata Participants (PHASE1, PHASE2)
- A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of IMG-007 in Adults With Atopic Dermatitis (AD) (PHASE1, PHASE2)
- Safety and Pharmacokinetics of Subcutaneous Dose of IMG-007 in Healthy Participants (PHASE1)
- Evaluate IMG-007 in Healthy Participants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IMG-007 CI brief — competitive landscape report
- IMG-007 updates RSS · CI watch RSS
- Inmagene LLC portfolio CI